GLP-1 Medications List: Every Drug, Brand, and Use (2026)

This GLP-1 medications list covers every FDA-approved GLP-1 receptor agonist and dual or triple incretin agonist in use in 2026, organised by active ingredient, brand name, drug type, approved use, and dosing form. There are far more of these drugs than the two everyone talks about. Below is the full comparison table first, then short notes on each medication and the emerging pipeline, so you can see exactly how the whole class fits together.

One fact untangles most of the confusion in any list of GLP-1 medications: the same molecule is often sold under two different brand names, one approved for type 2 diabetes and one for weight management. Semaglutide is both Ozempic and Wegovy. Tirzepatide is both Mounjaro and Zepbound. The drug is identical; the brand, dose ceiling, and label differ. Keep that in mind as you read the table.

The complete GLP-1 medications list (2026 comparison table)

Here is the full list of GLP-1 medications and related incretin drugs, with the details that actually distinguish them. "Drug type" tells you which gut-hormone receptors the molecule activates; the wider family is explained in our overview of the GLP-1 receptor agonist drug class.

Active ingredient	Brand name(s)	Drug type	FDA-approved use	Dosing form	Approval status
Semaglutide	Ozempic	GLP-1	Type 2 diabetes (+ cardiovascular risk)	Weekly injection	Approved 2017
Semaglutide	Wegovy	GLP-1	Weight management (+ cardiovascular risk)	Weekly injection	Approved 2021
Semaglutide	Rybelsus	GLP-1	Type 2 diabetes	Daily oral tablet	Approved 2019
Semaglutide	Wegovy (oral pill)	GLP-1	Weight management	Daily oral tablet	Approved 2025/2026
Tirzepatide	Mounjaro	GLP-1 / GIP (dual)	Type 2 diabetes	Weekly injection	Approved 2022
Tirzepatide	Zepbound	GLP-1 / GIP (dual)	Weight management; obstructive sleep apnoea	Weekly injection	Approved 2023
Liraglutide	Victoza	GLP-1	Type 2 diabetes (+ cardiovascular risk)	Daily injection	Approved 2010
Liraglutide	Saxenda	GLP-1	Weight management	Daily injection	Approved 2014
Dulaglutide	Trulicity	GLP-1	Type 2 diabetes (+ cardiovascular risk)	Weekly injection	Approved 2014
Exenatide	Byetta	GLP-1	Type 2 diabetes	Twice-daily injection	Approved 2005; US supply discontinued
Exenatide ER	Bydureon BCise	GLP-1	Type 2 diabetes	Weekly injection	Approved 2012; US supply discontinued
Lixisenatide	Adlyxin	GLP-1	Type 2 diabetes	Daily injection	Approved 2016; limited US availability
Orforglipron	(Eli Lilly brand)	GLP-1 (oral small molecule)	Overweight/obesity; diabetes under review	Daily oral tablet	Newly approved 2026
Retatrutide	(investigational)	GLP-1 / GIP / glucagon (triple)	None yet	Weekly injection	Investigational (phase 3)

Two fixed-dose combination injectables also contain a GLP-1 drug paired with long-acting insulin for type 2 diabetes: Soliqua (lixisenatide plus insulin glargine) and Xultophy (liraglutide plus insulin degludec). They sit at the edge of this list because the GLP-1 is only one half of the product.

Types of GLP-1 on the list: single, dual, and triple agonists

The clearest way to read any list of GLP-1 medications is by drug type, because that is what drives how strongly each one works. A fuller mechanistic account lives in what a GLP-1 medication is; here is the short version.

Single GLP-1 agonists activate one receptor, the GLP-1 receptor. This is the original and largest group: semaglutide, liraglutide, dulaglutide, exenatide, and lixisenatide. They reduce appetite, slow gastric emptying, and improve blood-sugar control.

Dual GLP-1/GIP agonists add a second incretin receptor, GIP. Tirzepatide is the only one on the market, and engaging both pathways produced larger average weight loss in trials than single-receptor drugs. The details are in how tirzepatide works.

Triple agonists add a third target, the glucagon receptor, which may raise energy expenditure on top of suppressing appetite. Retatrutide is the lead candidate and remains investigational; see the newest GLP-1 drugs and retatrutide for where that stands.

Semaglutide: Ozempic, Wegovy, Rybelsus, and the oral pill

Semaglutide is the most widely used name on this GLP-1 drugs list, sold under several brands. A plain-English primer is in semaglutide explained.

Ozempic (weekly injection, type 2 diabetes)

Approved in 2017 at doses of 0.5 mg, 1 mg, and 2 mg weekly. It also carries an indication for reducing cardiovascular risk in adults with type 2 diabetes and established cardiovascular disease.

Wegovy (weekly injection, weight management)

Approved in 2021, the same molecule titrated higher (up to 2.4 mg weekly) and labelled for chronic weight management in adults with obesity, or overweight plus a weight-related condition, and for adolescents aged 12 and up. It also carries a cardiovascular-event-reduction indication. Because Ozempic and Wegovy are the same drug under different labels, see Ozempic vs Wegovy for which applies to you.

Rybelsus (daily oral tablet, type 2 diabetes)

Approved in 2019 as the first oral GLP-1 receptor agonist, at 3 mg, 7 mg, and 14 mg daily. It must be taken on an empty stomach with a small sip of water, then a 30-minute wait before eating or other medication.

Wegovy oral pill (daily tablet, weight management)

An oral semaglutide pill for weight management reached the US market for the 2025 to 2026 period, the first oral GLP-1 approved for weight loss rather than diabetes. It widens access for people who would rather not inject, with a higher daily dose than Rybelsus.

Semaglutide's effect on appetite and the brain is covered in how semaglutide works for weight loss.

Tirzepatide: Mounjaro and Zepbound

Tirzepatide is the only dual GLP-1/GIP agonist on this list of GLP-1 medications, and the most potent currently approved.

Mounjaro (weekly injection, type 2 diabetes)

Approved in 2022, titrated from 2.5 mg to 15 mg weekly. It produced some of the largest HbA1c reductions recorded for a diabetes drug.

Zepbound (weekly injection, weight management)

Approved in 2023, the same molecule and doses labelled for weight management, with a later indication for moderate-to-severe obstructive sleep apnoea in adults with obesity. In the SURMOUNT-1 trial the highest dose produced about 20.9% mean weight loss over 72 weeks. Because the two brands are identical molecules, read Mounjaro vs Zepbound before assuming one is stronger than the other.

Older GLP-1 drugs: liraglutide, dulaglutide, exenatide, lixisenatide

These earlier agents still appear on the list and remain options where cost, formulary placement, or tolerability favour them, though the trials show smaller average effects than semaglutide or tirzepatide.

Liraglutide (Victoza and Saxenda)

A daily injection and one of the earliest GLP-1 drugs in mainstream use. Victoza (approved 2010, up to 1.8 mg) treats type 2 diabetes and reduces cardiovascular risk. Saxenda (approved 2014, titrated to 3 mg) was the first GLP-1 approved specifically for weight management and is licensed for adults and adolescents aged 12 and up. Both have largely been displaced by weekly options.

Dulaglutide (Trulicity)

A weekly injection approved in 2014, at 0.75 mg to 4.5 mg, with cardiovascular-outcomes data. An established weekly diabetes option that has been superseded on efficacy by the newer molecules but stays in use where cost or familiarity guides prescribing.

Exenatide (Byetta and Bydureon BCise)

Exenatide was the first GLP-1 receptor agonist approved in the US, in 2005, derived from a peptide in Gila monster venom. Byetta is twice-daily; Bydureon BCise is an extended-release weekly form. Both are now rarely used, and the manufacturer has discontinued their US supply.

Lixisenatide (Adlyxin)

A once-daily injection approved in 2016 for type 2 diabetes. It is the least-prescribed standalone GLP-1 in the US, though the molecule lives on in the Soliqua combination product.

Emerging and newest GLP-1 drugs to watch

The list keeps growing, and several agents are moving the boundary of what these drugs do. Approval status here changes faster than anywhere else on the list, so treat this as a snapshot.

Orforglipron is a once-daily, non-peptide oral GLP-1 receptor agonist from Eli Lilly. As a small molecule it can be manufactured at scale and taken without food or water restrictions, unlike peptide pills such as Rybelsus. It reached the market in 2026 for overweight and obesity, with a diabetes use under review, and is widely expected to expand access because of its oral form and supply profile.

Retatrutide is the lead triple agonist, hitting GLP-1, GIP, and glucagon receptors at once. Early-phase data showed weight loss at the high end of anything reported so far, but it remains investigational and is not yet approved. Our dedicated page on retatrutide and the newest GLP-1 drugs tracks its progress.

Beyond these, the pipeline includes additional oral small molecules, once-monthly injectables, and further multi-agonist combinations. The direction is clear: more oral options, more receptors engaged per molecule, and broader supply.

What sets the newest entries apart is less the mechanism than the format. The original list was almost entirely peptide injections, which need cold-chain storage and a needle. Small-molecule oral drugs change that math: they are cheaper to manufacture, easier to store, and remove the injection barrier that keeps some people off treatment entirely. If the oral agents match the injectables on weight loss in head-to-head data, the centre of gravity on this list will shift toward pills over the next few years.

Which GLP-1 medication on this list is right for you?

A list cannot make the choice; a prescriber does, based on your indication, other conditions, tolerability, insurance, and cost. A few patterns help orient the decision. If you have type 2 diabetes, the diabetes-labelled brands (Ozempic, Mounjaro, Trulicity, Victoza) are the on-label route. If the goal is weight management without diabetes, only Wegovy, Zepbound, and Saxenda are approved for that use. For the largest average weight loss among approved drugs, the comparison generally comes down to tirzepatide versus semaglutide, which we lay out in the best GLP-1 for weight loss.

Two practical factors then narrow the list further. The first is form: if injecting is a hard no, the oral options (Rybelsus, the oral Wegovy pill, orforglipron) move up the shortlist even though the strongest weight-loss data still sits with the weekly injectables. The second is access. These drugs are expensive and coverage varies by indication, so the brand your insurer covers, or the lowest legitimate cash price, often decides the answer as much as the clinical ranking does. For the full picture of how the class works and what the trials show, see the complete guide to GLP-1 medications.

Want clear, unbiased GLP-1 guidance without the sales pitch? Modern Weight Science is independent and evidence-based. Subscribe to our free weekly newsletter for plain-English updates on the medications, access, and the science, with no spam and no product pitches.

FDA approvals, available doses, and brand availability change over time. This list reflects publicly available information as of June 2026. Always confirm current approvals and indications with your prescriber or the FDA's official drug database before making any decision.